ABIOLA GRANT: Open Payments
NPI 1508405044 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,831 in 131 payments from 23 companies in 2025. Trend: 2023 $1,243 · 2024 $1,883 · 2025 $2,831
Food & beverage: $2,762Education: $69
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 34 | $799 |
| ABBVIE INC. | 34 | $537 |
| Otsuka America Pharmaceutical, Inc. | 20 | $467 |
| GlaxoSmithKline, LLC. | 11 | $196 |
| Amgen Inc. | 4 | $186 |
| Astellas Pharma US Inc | 2 | $85 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $84 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Novo Nordisk Inc | 2 | $48 |
| Inspire Medical Systems, Inc. | 2 | $44 |
Products named: REXULTI, VRAYLAR, FARXIGA, BREZTRI, Repatha, NUCALA, TRELEGY ELLIPTA, XIFAXAN.
Industry payments across CT — which companies pay providers there.
